Preclinical report suggests combined ARSB and pembrolizumab inhibits melanoma progression in mice
Mouse model shows combined ARSB and pembrolizumab slows melanoma growth
This preclinical report evaluates the combination of recombinant human Arylsulfatase B (ARB) and pembrolizumab in a B16F10 syngeneic mouse m…
In a lab mouse model, combining a specific enzyme with pembrolizumab slowed tumor growth and improved survival, offering early clues for fut…
Retrospective analysis identifies molecular correlates of benefit with encorafenib-based therapy in BRAF-mutant melanoma
Melanoma study finds tumor genetics and immune markers may predict treatment benefit
A retrospective exploratory analysis of the phase III COLUMBUS trial in 921 patients with BRAF V600E/K-mutant advanced melanoma found that s…
Patients with advanced melanoma who have higher tumor mutational burden or signs of immune system activity gain the most survival benefit fr…
Phase 2 study of lifileucel TIL therapy in 220 patients with metastatic melanoma
Can a patient's own immune cells be turned into a treatment for advanced melanoma?
A prospective, multicenter, phase 2 interventional study evaluated lifileucel (autologous tumor-infiltrating lymphocytes, LN-144) infusion a…
A new treatment uses a patient's own immune cells to fight advanced melanoma, but results from the mid-stage trial are not yet available.